CMS considers expanding MolDX‑style oversight nationwide.

According to recent analyses, **billions of dollars in fraudulent Medicare payments** have flowed through non‑MolDX jurisdictions, particularly in states where pop‑up labs were able to bill tens of millions of dollars for inappropriate or impossible genetic tests with little pre‑payment scrutiny. In one case, a Florida MAC paid out enormous sums for high‑cost hereditary panels in elderly nursing‑home patients—tests that should never have been ordered—before the lab simply switched to adjacent codes and continued billing. These patterns have persisted for years in non‑MolDX regions, while **MolDX‑managed MACs have maintained tighter controls, standardized coding, and more consistent test validation**. CMS is now asking stakeholders whether **national MolDX‑style registration, coding validation, and evidence requirements** would reduce fraud, waste, and abuse across molecular diagnostics. The agency specifically wants input on why commercial payers and Medicare Advantage plans already require MolDX registration—even outside MolDX states—and what safeguards MolDX provides that standard MAC oversight does not. If CMS moves toward broader MolDX‑like oversight, the implications for the diagnostics industry will be significant. Evidence requirements will rise. Coding pathways will tighten. Smaller labs may face new compliance burdens. And established manufacturers could benefit from **more predictable, nationally consistent reimbursement frameworks**. This is a pivotal moment for molecular diagnostics. Regulatory expectations are shifting, fraud enforcement is intensifying, and payers are demanding stronger evidence and clearer clinical utility. Companies that understand these dynamics—and plan for them—will be positioned to lead. **GRN IVD Consulting** supports diagnostics manufacturers, investors, and health‑system leaders with **customized market intelligence** across molecular testing, reimbursement strategy, and payer‑driven evidence requirements. Our tailored reports help teams anticipate regulatory shifts, evaluate competitive landscapes, and build strategies aligned with where the market is heading. As CMS considers expanding MolDX‑style oversight nationwide, organizations need clarity more than ever. GRN IVD Consulting delivers the strategic insight required to navigate this evolving environment with confidence. To explore the impications contact grnivdconsulting@gmail.com